RecruitingNCT06657846
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome
Health-Related Quality of Life and Financial Toxicity in Patients With VEXAS Syndrome: An Italian GIMEMA Study
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Enrollment
100 participants
Start Date
Nov 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This multicenter cross-sectional observational study aims to describe health-related quality of life (HRQoL) and symptom profiles of patients with VEXAS syndrome.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Plain Language Summary
Simplified for easier understanding
This study looks at quality of life and the financial burden experienced by people diagnosed with VEXAS syndrome — a rare inflammatory disease caused by a genetic mutation that affects blood cells and causes widespread inflammation. The study uses surveys to understand the real-world impact of living with this condition.
**You may be eligible if...**
- You are 18 or older
- You have a confirmed diagnosis of VEXAS syndrome (detected through a specific gene mutation called UBA1)
- You can provide written consent
**You may NOT be eligible if...**
- You have a psychiatric disorder or significant cognitive impairment
- You cannot read or understand the local language used in the study
Talk to your doctor to see if this trial is right for you.
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06657846